1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drugs In Development, 2022, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 11, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Co
- Corcept Therapeutics Inc
- Eisai Co Ltd
- Enterome Bioscience SA
- Exelixis Inc
- Fusion Pharmaceuticals Inc
- GSK plc
- Infinity Pharmaceuticals Inc
- Merck & Co Inc
- Merck KGaA
- Orphagen Pharmaceuticals Inc
- Pharma Mar SA
- Sanofi
- Seneca Therapeutics Inc
- Tempest Therapeutics Inc
- Y-mAbs Therapeutics Inc
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
- 8H-9 - Drug Profile
- Product Description
- Mechanism Of Action
- avelumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cabazitaxel - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cabometyx - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- derazantinib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dostarlimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ecubectedin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- eganelisib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EO-2401 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FPI-1434 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ipilimumab + nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lenvatinib mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nevanimibe hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- niraparib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- omburtamab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OR-449 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pembrolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- relacorilant - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SVV-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
- Featured News & Press Releases
- Jun 14, 2022: Orphagen Pharmaceuticals presents data on downstream targets of SF-1 Antagonist OR-449 at ENDO 2022
- Jun 04, 2018: Infinity Reports IPI-549 Clinical and Translational Data from Ongoing Phase 1/1b Study at American Society of Clinical Oncology Annual Meeting
- Jan 08, 2018: Infinity Provides Update on IPI-549 Phase I/Ib Study, 2018 Goals and Financial Guidance
- Nov 10, 2017: Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting
- Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
- Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
- Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
- Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
- Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Corcept Therapeutics Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Eisai Co Ltd, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Enterome Bioscience SA, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Fusion Pharmaceuticals Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by GSK plc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck & Co Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Pharma Mar SA, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Sanofi, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Seneca Therapeutics Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Tempest Therapeutics Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Y-mAbs Therapeutics Inc, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, 2022
- Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, 2022
- Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Co
- Corcept Therapeutics Inc
- Eisai Co Ltd
- Enterome Bioscience SA
- Exelixis Inc
- Fusion Pharmaceuticals Inc
- GSK plc
- Infinity Pharmaceuticals Inc
- Merck & Co Inc
- Merck KGaA
- Orphagen Pharmaceuticals Inc
- Pharma Mar SA
- Sanofi
- Seneca Therapeutics Inc
- Tempest Therapeutics Inc
- Y-mAbs Therapeutics Inc
